Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oculocutaneous albinism.
Goldberg RA, Lally DR, Heier JS. Goldberg RA, et al. Among authors: lally dr. JAMA Ophthalmol. 2015 Mar;133(3):e143518. doi: 10.1001/jamaophthalmol.2014.3518. Epub 2015 Mar 12. JAMA Ophthalmol. 2015. PMID: 25763554 No abstract available.
Natural history of Valsalva-induced subhyaloid hemorrhage.
Szelog JT, Lally DR, Heier JS. Szelog JT, et al. Among authors: lally dr. JAMA Ophthalmol. 2015 Feb;133(2):e143268. doi: 10.1001/jamaophthalmol.2014.3268. Epub 2015 Feb 12. JAMA Ophthalmol. 2015. PMID: 25674894 No abstract available.
Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.
Khanani AM, Patel SS, Staurenghi G, Tadayoni R, Danzig CJ, Eichenbaum DA, Hsu J, Wykoff CC, Heier JS, Lally DR, Monés J, Nielsen JS, Sheth VS, Kaiser PK, Clark J, Zhu L, Patel H, Tang J, Desai D, Jaffe GJ; GATHER2 trial investigators. Khanani AM, et al. Among authors: lally dr. Lancet. 2023 Oct 21;402(10411):1449-1458. doi: 10.1016/S0140-6736(23)01583-0. Epub 2023 Sep 8. Lancet. 2023. PMID: 37696275
Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.
Heier JS, Lad EM, Holz FG, Rosenfeld PJ, Guymer RH, Boyer D, Grossi F, Baumal CR, Korobelnik JF, Slakter JS, Waheed NK, Metlapally R, Pearce I, Steinle N, Francone AA, Hu A, Lally DR, Deschatelets P, Francois C, Bliss C, Staurenghi G, Monés J, Singh RP, Ribeiro R, Wykoff CC; OAKS and DERBY study investigators. Heier JS, et al. Among authors: lally dr. Lancet. 2023 Oct 21;402(10411):1434-1448. doi: 10.1016/S0140-6736(23)01520-9. Lancet. 2023. PMID: 37865470 Clinical Trial.
Foveal injury from a red laser pointer.
Lally DR, Duker JS. Lally DR, et al. JAMA Ophthalmol. 2014 Mar;132(3):297. doi: 10.1001/jamaophthalmol.2014.34. JAMA Ophthalmol. 2014. PMID: 24626822 No abstract available.
41 results